Bayer Pharmaceuticals A pharmaceutical company focusing on innovation to improve patient’s quality of life and answer unmet medical needs

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.

In the fiscal year 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros globally. Our spending on Research & Development amounted to 5.3 billion euros. Bayer has been present in the BeNeLux region for over a century, currently with about 2100 people.

© Bayer Group - Cardiologist at a microscope



© Bayer Group - Thrombosis researcher

Bayer’s Global Divisions

Bayer has three global divisions: Pharmaceuticals, Consumer Health and Crop Science.

Consumer Health

Consumer Health supplies over-the-counter products offering a range of healthcare and wellbeing solutions with products in women’s health, analgesics, digestive health, skincare, nutrition, allergy, and foot care.

Crop Science

Crop Science provides innovative crop protection solutions and seeds.

Deep dive into Pharmaceuticals

Bayer Pharmaceuticals focuses on creating innovative prescription medicines for diseases with a high unmet medical need with the aim to improve patients' quality of life and prolong lives. We focus on the therapeutic areas of ophthalmology, cardiology, oncology, women's health, hematology, and radiology.

Although we will continue to invest in small molecules – relatively simple chemical compounds – and biologics – drug products based on biological sources – the next milestone in fighting diseases is cell and gene therapy. We have heavily invested in this area by our recent acquisitions of Bluerock and AskBio.

These acquisitions bring together the best of two worlds: co-operation with deeply specialized and fast-moving teams in the biotech sector and Bayer's expertise in developing, producing, and bringing to market new products and solutions. Our partnership with Mammoth Biosciences allows us to work together on improving the CRISPR-technology that enables gene editing.

With cell and gene therapy, we will try to target illnesses at their source, and we have the potential to shift from treating symptoms to curing diseases. An exciting prospect!

Bayer SA-NV
J.E. Mommaertslaan 14
B-1831 Diegem (Machelen)
Tel.: +32 (0)2 535 63 11
http://www.bayer.be
COR-OTH-BE-0001-1